- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07703891
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
Přehled studie
Postavení
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Teniola Egbe, MPH, MBE
- Telefonní číslo: 215-898-2939
- E-mail: tegbe@pennmedicine.upenn.edu
Studijní záloha kontaktů
- Jméno: Divya Pandey, PhD
- Telefonní číslo: 6123230324
- E-mail: Divya.Pandey@PennMedicine.upenn.edu
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Aged 18 years or older
- Residing in Gauteng
- Able to understand and communicate in English or another study-supported language
- Willing to attend an in-person study visit at the HE2RO offices
- Willing to provide contact details for follow-up at six weeks
Exclusion Criteria:
- Unwilling or unable to provide written informed consent for study participation
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Control
Participants enrolled in the control group will receive standard-of-care verbal information about HIV and ART based on South African Department of Health guidelines, delivered via standardized script.
|
Participants enrolled in this group will receive standard-of-care verbal information about HIV and ART based on South African Department of Health guidelines, delivered via standardized script.
|
|
Experimentální: B-OK Bottles Intervention (delivered in person)
Participants enrolled in this group will receive information about HIV and ART that is communicated using B-OK bottles as visual aids to make the information more salient.
The bottles explain how HIV affects a person's health and how ART reduces viral load and eliminates HIV transmission risk.
|
Participants in this group will receive information about HIV and ART that is communicated using B-OK bottles as visual aids to make the information more salient.
The bottles explain how HIV affects a person's health and how ART reduces viral load and eliminates HIV transmission risk.
|
|
Experimentální: B-OK Bottles Intervention (delivered by video)
Participants enrolled in this group will receive information about HIV and ART in the form of a video that illustrates B-OK.
The video will use the bottles to explain how HIV affects a person's health and how ART reduces viral load and eliminates HIV transmission risk.
|
Participants in this group will receive information about HIV and ART in the form of a video that illustrates the B-OK bead bottles and how they work.
The video will demonstrate use of the B-OK bead bottles to explain how HIV affects a person's health and how ART reduces viral load and eliminates HIV transmission risk.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Accuracy of beliefs about ART effectiveness (composite), post-intervention
Časové okno: Immediately post-intervention
|
A composite score will be derived from two items assessing beliefs about the effectiveness of HIV treatment, each scored 0-10: (1) prevention benefit - "Imagine a person living with HIV who is taking HIV treatment and has an undetectable viral load. How likely is it that this person would pass HIV to a regular sexual partner?"; (2) clinical benefit - "Imagine a person living with HIV who is taking HIV treatment and has an undetectable viral load. How likely is it that this person would be harmed by HIV?" The two items will be combined into a composite, to be pre-specified in the statistical analysis plan; lower scores indicate more accurate beliefs about the prevention and clinical benefits of HIV treatment with viral suppression. |
Immediately post-intervention
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Accuracy of U=U transmission-risk belief
Časové okno: Immediately post-intervention and 6 weeks follow-up
|
The outcome will be measured on a 0-10 scale, based on this question: "Imagine a person living with HIV who is taking HIV treatment and has an undetectable viral load.
How likely is it that this person would pass HIV to a regular sexual partner?"
Minimum 0, maximum 10; lower scores indicate more accurate beliefs consistent with U=U.
|
Immediately post-intervention and 6 weeks follow-up
|
|
Accuracy of belief about personal harm under viral suppression
Časové okno: Immediately post-intervention and 6 weeks follow-up
|
The outcome will be measured on a 0-10 scale, based on this question: "Imagine a person living with HIV who is taking HIV treatment and has an undetectable viral load.
How likely is it that this person would be harmed by HIV?" Minimum 0, maximum 10; lower scores indicate more accurate belief.
|
Immediately post-intervention and 6 weeks follow-up
|
|
Accuracy of beliefs about ART effectiveness (composite), follow-up
Časové okno: 6 weeks follow-up
|
A composite score will be derived from two items assessing beliefs about the effectiveness of HIV treatment, each scored 0-10: (1) prevention benefit - "Imagine a person living with HIV who is taking HIV treatment and has an undetectable viral load. How likely is it that this person would pass HIV to a regular sexual partner?"; (2) clinical benefit - "Imagine a person living with HIV who is taking HIV treatment and has an undetectable viral load. How likely is it that this person would be harmed by HIV?" The two items will be combined into a composite, to be pre-specified in the statistical analysis plan; lower scores indicate more accurate beliefs about the prevention and clinical benefits of HIV treatment with viral suppression. |
6 weeks follow-up
|
|
Comprehension of "viral suppression"
Časové okno: Immediately post-intervention and 6 weeks follow-up
|
This outcome measures self-rated understanding of the term "viral suppression," based on the question: "How well do you understand the term 'viral suppression'?"
Measured on a 0-10 scale.
Minimum 0, maximum 10; higher scores indicate greater comprehension.
|
Immediately post-intervention and 6 weeks follow-up
|
|
Comprehension of "U=U" / "Undetectable=Untransmittable"
Časové okno: Immediately post-intervention and 6 weeks follow-up
|
This outcome measures self-rated understanding of the term "U=U" or "Undetectable=Untransmittable," based on the question: "How well do you understand the term 'U=U' or 'Undetectable=Untransmittable'?" Measured on a 0-10 scale.
Minimum 0, maximum 10; higher scores indicate greater comprehension.
|
Immediately post-intervention and 6 weeks follow-up
|
|
Attitude - residual transmission concern despite ART
Časové okno: Immediately post-intervention and 6 weeks follow-up
|
The outcome measures agreement that HIV medication does not completely eliminate the risk of getting HIV through sex.
Measured on a 0-10 scale.
Minimum 0, maximum 10; higher scores indicate greater concern.
|
Immediately post-intervention and 6 weeks follow-up
|
|
Attitude - HIV fatalism
Časové okno: Immediately post-intervention and 6 weeks follow-up
|
This outcome measures agreement with "Having HIV means I will eventually die from it". Measured on a 0-10 scale. Minimum 0, maximum 10; higher scores indicate higher fatalistic beliefs about HIV. |
Immediately post-intervention and 6 weeks follow-up
|
|
Intention - condom use under hypothetical viral suppression
Časové okno: Immediately post-intervention and 6 weeks follow-up
|
This outcome measures self-rated likelihood of using a condom to prevent transmission to an HIV-negative partner, in a hypothetical scenario where the participant is virally suppressed on treatment. Measured on a 0-10 scale. Minimum 0, maximum 10; higher scores indicate greater likelihood of condom use. |
Immediately post-intervention and 6 weeks follow-up
|
|
Intention - motivation to initiate or continue ART
Časové okno: Immediately post-intervention and 6 weeks follow-up
|
This outcome measures the self-rated motivation to stay on or restart HIV treatment. Measured on a 0-10 scale. Minimum 0, maximum 10; higher scores indicate greater motivation. For participants living with HIV, the question refers to their own treatment; for participants who are HIV-negative or of unknown status, it is framed as a hypothetical scenario. |
Immediately post-intervention and 6 weeks follow-up
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Aaron Richterman, PhD, University of Pennsylvania
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 26-6783
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na HIV
-
Duke UniversityGilead SciencesNáborPrevence HIV | Pre-expoziční profylaxe HIV | Program prevence HIV | Prevence a péče o HIV | Pre-expoziční profylaxe HIVSpojené státy
-
Federal University of São PauloGilead SciencesDokončeno
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthNáborHIV | Testování HIV | HIV vazba na péči | Léčba HIVSpojené státy
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH)NáborPrevence HIV | Dodržování PrEP | HIV Související StigmaThajsko
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)NáborPřípravka | HIV | Prevence HIV | Vychytávání PrEPSpojené státy
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)NáborProveditelnost | Prevence HIV | Vychytávání PrEP | Přijatelnost | Samotestování HIV | Muž partneři HIV-negativní poporodní ženyJižní Afrika
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement a další spolupracovníciNeznámýHIV | Děti neinfikované HIV | Děti vystavené HIVKamerun
-
ANRS, Emerging Infectious DiseasesZatím nenabírámeAntiretrovirová terapie | HIV-1 infekce | Zásobník HIV
-
University of MinnesotaStaženoHIV infekce | HIV/AIDS | Hiv | AIDS | Problém AIDS/Hiv | AIDS a infekceSpojené státy
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationDokončenoPartnerské HIV testování | Poradenství pro pár HIV | Párová komunikace | Výskyt HIVKamerun, Dominikánská republika, Gruzie, Indie
Klinické studie na Control
-
Linkoeping UniversityThe Swedish Research Council; the Swedish Research Council for Health, Working...NáborPřilnavost | Prevence zranění ve sportuŠvédsko
-
Essilor InternationalDokončeno
-
Linkoeping UniversityThe Swedish Research Council; Swedish Research Council for Sport ScienceDokončeno
-
Rigshospitalet, DenmarkUniversity of CopenhagenAktivní, ne náborStádium nemalobuněčného karcinomu plic | ChemoradiaceDánsko
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)DokončenoHypertenze | Chronická onemocnění ledvin | Chronické onemocnění | Chronické onemocnění ledvin Fáze 5 | Chronické onemocnění ledvin, stadium 4 (závažné) | Chronické onemocnění ledvin, fáze 3 (střední)Spojené státy
-
Tandem Diabetes Care, Inc.NáborKontrola reálného světa-IQ Glykemic a studie kvality života u diabetu 1. typu ve Francii (RECORD-IQ)Diabetes mellitus, typ 1Francie
-
Gangnam Severance HospitalDokončenoPacienti s adenokarcinomem žaludku, kteří jsou naplánováni na laparoskopickou radikální gastrektomiiKorejská republika
-
Singapore General HospitalDuke-NUS Graduate Medical SchoolNeznámýKardiovaskulární choroby | Hypertenze | Chronická onemocnění ledvinSingapur
-
University of California, San FranciscoStaženoAkutní poranění plic
-
Newsoara Biopharma Co., Ltd.Nábor